• 1

    Mcllwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease. Equine Vet J Suppl 1988;6:311.

  • 2

    Lust G, Williams AJ, Burton-Wurster N, et al. Effects of intramuscular administration of glycosaminoglycan polysulfates on signs of incipient hip dysplasia in growing pups. Am J Vet Res 1992;53:18361843.

    • Search Google Scholar
    • Export Citation
  • 3

    Todhunter RJ, Lust G. Polysulfated glycosaminoglycan in the treatment of osteoarthritis. J Am Vet Med Assoc 1994;204:12451251.

  • 4

    Trotter GW. Polysulfated glycosaminoglycan. In:Mcllwraith CW, Trotter GW, ed.Joint disease in the horse. Philadelphia: WB Saunders, 1996;270280.

    • Search Google Scholar
    • Export Citation
  • 5

    Sevalla K, Todhunter RJ, Vernier-Singer M, et al. Effect of polysulfated glycosaminoglycan on DNA content and proteoglycan metabolism in normal and osteoarthritic canine articular cartilage explants. Vet Surg 2000;29:407414.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Glade MJ. Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycans by arthritic equine cartilage tissues and chondrocytes. Am J Vet Res 1990;51:779785.

    • Search Google Scholar
    • Export Citation
  • 7

    Hedbom E, Antonssson P, Hjerpe A, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992;267:61326136.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    DiCesare PE, Mörgelin M, Carlson CS, et al. Cartilage oligomeric matrix protein: isolation and characterization from human articular cartilage. J Orthop Res 1995;13:422428.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    DiCesare PE, Carlson CS, Stollerman ES, et al. Expression of cartilage oligomeric matrix protein by human synovium. FEBS Lett 1997;412:249252.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998;41:9971006.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11

    DiCesare PE, Hauser N, Lehman D. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994;354:237240.

  • 12

    Smith RKW, Zunino L, Webbon PM, et al. The distribution of cartilage oligomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. Matrix Biol 1997;16:255271.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13

    Vogel KG, Meyers AB. Proteins in the tensile region of adult bovine deep flexor tendon. Clin Orthop 1999;367S:S344S355.

  • 14

    Morgelin M, Heinegård D, Engel J, et al. Electron microscopy of native cartilage oligomeric matrix protein purified from the swarm rat chondrosarcoma reveals a five-armed structure. J Biol Chem 1992;267:61376141.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    DiCesare PE, Mörgelin M, Mann K, et al. Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 1994;223:927937.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:23562364.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Steffey MA, Miura N, Todhunter RJ, et al. The potential and limitations of cartilage-specific (V+C) fibronectin and cartilage oligomeric matrix protein as osteoarthritis biomarkers in canine synovial fluid. Osteoarthritis Cartilage 2004;12:818825.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18

    Misumi K, Vilim V, Carter SD, et al. Concentrations of cartilage oligomeric matrix protein in dogs with naturally developing and experimentally induced arthropathy. Am J Vet Res 2002;63:598603.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19

    Brandt KD, Mankin HJ. Workshop on the etiopathogenesis of osteoarthritis. J Rheumatol 1986;13:11261160.

  • 20

    Koolwijk P, Miltenburg AM, vanErck MG, et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 1995;22:385393.

    • Search Google Scholar
    • Export Citation
  • 21

    Coughlan AR, Robertson DH, Bennett D, et al. Matrix metalloproteinase 2 and 9 in canine rheumatoid arthritis. Vet Rec 1998;143:219223.

  • 22

    Volk SW, Kapatkin AS, Haskins ME, et al. Gelatinase activity in synovial fluid and synovium obtained from healthy and osteoarthritic joints of dogs. Am J Vet Res 2003;64:12251233.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23

    Clegg PD, Burke RM, Coughlan AR, et al. Characterisation of equine matrix metalloproteinase 2 and 9; and identification of the cellular sources of these enzymes in joints. Equine Vet J 1997;29:335342.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24

    Fosang AJ, Neame PJ, Last K, et al. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992;267:1947019474.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25

    Clegg PD, Coughlan AR, Riggs CM, et al. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997;29:343348.

  • 26

    DeHaan JJ, Goring RL, Beale BS. Evaluation of polysulfated glycosaminoglycan for the treatment of hip dysplasia in dogs. Vet Surg 1994;23:177181.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27

    McNamara PS, Johnston SA, Thodhunter RJ. Slow-acting disease-modifying osteoarthritis agents. Vet Clin North Am Small Anim Pract 1997;27:863881.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28

    Cross AR, Budsberg SC, Keef TJ. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997;58:626631.

    • Search Google Scholar
    • Export Citation
  • 29

    Budsburg SC, Johnston SA, Schwarz PD, et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999;214:206210.

    • Search Google Scholar
    • Export Citation
  • 30

    Misumi K, Vilim V, Clegg PD, et al. Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids. Osteoarthritis Cartilage 2001;9:119127.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31

    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680685.

  • 32

    Vilim V, Lenz ME, Vytasek R, et al. Characterization of monoclonal antibodies recognizing different fragments of cartilage oligomeric matrix protein in human body fluids. Arch Biochem Biophys 1997;341:816.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33

    Miya K, Misumi K, Miyoshi N, et al. Interpreting gelatinase activity in tumor tissue and serum as a progenostic marker of naturally developing canine tumors. J Vet Med Sci 2005;67:769775.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Keck T, Balcom JH IV, Fernandez-del Castillo C, et al. Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology 2002;122:188201.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35

    Clegg PD, Jones MD, Carter SD. The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. J Vet Pharmacol Ther 1998;21:406413.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Mertens WD, MacLeod JN, Fubini SL, et al. Polysulfated glycosaminoglycans modulate transcription of interleukin-1B treated chondrocytes in monolayer culture. Vet Comp Orthop Traumatol 2003;16:9398.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37

    Tung JT, Venta PJ, Caron JP. Inducible nitric oxide expression in equine articular chondrocytes: effects of anti-inflammatory compounds. Osteoarthritis Cartilage 2002;10:512.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38

    Hummel KM, Neidhart M, Vilim V, et al. Analysis of cartilage oligomeric matrix protein (COMP) in synovial fibroblasts and synovial fluid. Br J Rheumatol 1998;37:721728.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Lindhost E, Vail TP, Guilak F, et al. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. J Orthop Res 2000;18:269280.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40

    Muri P, Danova NA, Argyle DJ. Collagenolytic protease expression in cranial cruciate ligament and stifle synovial fluid in dogs with cranial cruciate ligament rupture. Vet Surg 2005;34:482490.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41

    Thompson CCM, Clegg PD, Carter SD. Differential regulation of gelatinases by transforming growth factor beta-1 in normal equine chondrocytes. Osteoarthritis Cartilage 2001;9:325331.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42

    Garnero P, Mazieres B, Gueguen A, et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005;32:697703.

    • Search Google Scholar
    • Export Citation
  • 43

    Weigel JP, Arnold G, Hicks DA, et al. Biomechanics of rehabilitation. Vet Clin North Am Small Anim Pract 2005;35:12551285.

Advertisement

Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protein and C-reactive protein concentrations, serum matrix metalloproteinase-2 and -9 activities, and lameness in dogs with osteoarthritis

Makoto FujikiLaboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

Search for other papers by Makoto Fujiki in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Joe ShinehaLaboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

Search for other papers by Joe Shineha in
Current site
Google Scholar
PubMed
Close
 BSc
,
Kazuto YamanokuchiLaboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

Search for other papers by Kazuto Yamanokuchi in
Current site
Google Scholar
PubMed
Close
 DVM
,
Kazuhiro MisumiLaboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

Search for other papers by Kazuhiro Misumi in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Hiroshi SakamotoLaboratory of Veterinary Surgery, Department of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.

Search for other papers by Hiroshi Sakamoto in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To investigate the effects of polysulfated glycosaminoglycan (PSGAG) treatment on serum cartilage oligomeric matrix protein (COMP) concentration, matrix metal-loproteinase-2 (MMP-2) and -9 (MMP-9) activities, C-reactive protein (CRP) concentration, and lameness scores in dogs with osteoarthritis.

Animals—16 dogs with osteoarthritis and 5 clinically normal dogs.

Procedures—Dogs with osteoarthritis had a history of chronic lameness, and osteophytes were observed on radiographic evaluation of the affected joint. Polysulfated glycosaminoglycan was administered IM twice a week for a total of 8 treatments to all dogs with osteoarthritis and to clinically normal control dogs.

Results—Lameness scores after PSGAG treatment in osteoarthritic dogs improved in 12 of the 16 dogs. Serum COMP concentrations in osteoarthritic dogs were significantly higher than in control dogs before treatment. Lameness scores in osteoarthritic dogs decreased significantly after treatment, compared with before treatment. Lameness scores of 9 dogs with hind limb lameness improved significantly after treatment; these dogs had corresponding decreases in serum COMP concentrations. After treatment, serum COMP concentrations and lameness scores of 7 dogs with forelimb lameness remained high and were significantly higher than those of dogs with hind limb lameness. Serum MMP-9 activities of dogs with forelimb lameness were significantly higher than in dogs with hind limb lameness after treatment.

Conclusions and Clinical Relevance—IM administration of PSGAG inhibited COMP degradation in dogs with osteoarthritis. Results indicate that decreases in serum COMP concentrations might be related to improvement in lameness after PSGAG treatment.

Abstract

Objective—To investigate the effects of polysulfated glycosaminoglycan (PSGAG) treatment on serum cartilage oligomeric matrix protein (COMP) concentration, matrix metal-loproteinase-2 (MMP-2) and -9 (MMP-9) activities, C-reactive protein (CRP) concentration, and lameness scores in dogs with osteoarthritis.

Animals—16 dogs with osteoarthritis and 5 clinically normal dogs.

Procedures—Dogs with osteoarthritis had a history of chronic lameness, and osteophytes were observed on radiographic evaluation of the affected joint. Polysulfated glycosaminoglycan was administered IM twice a week for a total of 8 treatments to all dogs with osteoarthritis and to clinically normal control dogs.

Results—Lameness scores after PSGAG treatment in osteoarthritic dogs improved in 12 of the 16 dogs. Serum COMP concentrations in osteoarthritic dogs were significantly higher than in control dogs before treatment. Lameness scores in osteoarthritic dogs decreased significantly after treatment, compared with before treatment. Lameness scores of 9 dogs with hind limb lameness improved significantly after treatment; these dogs had corresponding decreases in serum COMP concentrations. After treatment, serum COMP concentrations and lameness scores of 7 dogs with forelimb lameness remained high and were significantly higher than those of dogs with hind limb lameness. Serum MMP-9 activities of dogs with forelimb lameness were significantly higher than in dogs with hind limb lameness after treatment.

Conclusions and Clinical Relevance—IM administration of PSGAG inhibited COMP degradation in dogs with osteoarthritis. Results indicate that decreases in serum COMP concentrations might be related to improvement in lameness after PSGAG treatment.

Contributor Notes

Supported by The Japan Society for the Promotion of Science (grant No. 16380212).

Address correspondence to Dr. Fujiki.